CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intrinsic Medicine Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intrinsic Medicine Inc
500 Yale Avenue North
Phone: (206) 426-3624p:206 426-3624 SEATTLE, WA  98109  United States Fax: (302) 636-5454f:302 636-5454

Business Summary
Intrinsic Medicine Inc is a United States-based preclinical-stage therapeutics company. The Company's initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or Human Milk Oligosaccharides (HMOs) which directly modulate the immune system and other human cells as well as the gut microbiome. The Company's Oligosaccharide Medicines (OMs) are synthetic biology-produced drugs equivalent to HMOs. The Company's pipeline consists of human-identical milk oligosaccharide (HiMO) drug candidates, including OM001 (HiMO 3’sialyllactose), OM002 (HiMO 2’-fucosyllactose), and OM003 (HiMO 6’-sialyllactose). Its pipeline has the potential to treat gut-brain axis disorders (GBA), and certain inflammatory disorders. Its HiMO drug candidates is suitable for convenient oral administration. HiMO drug candidates enable a diverse pipeline of addressable diseases, both within a single HiMO drug candidate and across multiple HiMO drug candidates.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202112/31/2021YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer AlexanderMartinez 38 3/1/2021 3/1/2021
President, Chief Operating Officer, Director JasonFerrone 48 8/1/2018 8/1/2018
General Counsel, Vice President, Legal and Corporate Development, and Secretary DustinCrawford 40 9/1/2021 9/1/2021
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 8 (As of 3/15/2022)
Outstanding Shares: 11,290,099 (As of 5/4/2022)
Federal Tax Id: 834622006
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 7, 2024